BHVN Stock — Biohaven Ltd.

Biohaven Ltd. (BHVN)

Updated October 16, 2026.

BHVN is a Stock. Total return is 47.7% over the past 4.1 years, 70.8 points behind SPY at 118.5%.

Biohaven Ltd. is a biopharmaceutical company developing treatments across immunology, neuroscience, and oncology, with a pipeline spanning from preclinical research through Phase 3 clinical trials for conditions including Parkinson's disease, epilepsy, obesity, and various cancers. The company does not currently distribute to shareholders. Biohaven appeals to investors seeking exposure to clinical-stage biotech development with no current income component.

BHVN performance versus SPY

Price and return data through 2026-10-16.

Total return is 47.7% over the past 4.1 years, 70.8 points behind SPY at 118.5%. Over the past year its total return — price change plus distributions reinvested — is -34.6%. Its deepest 1-year drawdown was 57.0%.

BHVN key facts

Asset type

Stock

Asset class

Equity

Inception date

09/23/2022

Distribution frequency

None

Last close

$10.78 (as of 2026-10-16)

Market cap

$1,628,251,959

Average volume

2423654.0

Beta

3.203

Payout ratio

0.0%

EPS

$-4.56

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BHVN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.0%.

Who may consider BHVN — and who may not

It is a weaker fit for investors who need monthly cash flow (BHVN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BHVN

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions